DelMar to Present Poster of Clinical Research with VAL-083 in Patients with Chemo-Resistant Glioblastoma ("GBM") at ASCO Annual Meeting

VANCOUVER, British Columbia and MENLO PARK, Calif., April 27, 2017 /PRNewswire/ — DelMar Pharmaceuticals (Nasdaq: DMPI) (“DelMar” and the “Company”), a biopharmaceutical company focused on the develo…Read More »

DelMar Pharmaceuticals Collaborates with Duke University to Explore VAL-083 as a Front-Line Treatment for Glioblastoma Multiforme

VANCOUVER, British Columbia and MENLO PARK, Calif., April 25, 2017 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” and the “Company”), a biopharmaceutical company focused on the…Read More »

DelMar Pharmaceuticals Announces Closing Of $9,000,000 Public Offering Of Common Stock And Warrants

VANCOUVER, British Columbia and MENLO PARK, Calif., April 21, 2017 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the d…Read More »

DelMar Pharmaceuticals Announces Pricing Of $9,000,000 Public Offering Of Common Stock And Warrants

VANCOUVER, British Columbia and MENLO PARK, Calif., April 13, 2017 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the d…Read More »

DelMar Pharmaceuticals Announces Proposed Public Offering Of Common Stock And Warrants

VANCOUVER, British Columbia and MENLO PARK, Calif., April 12, 2017 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the d…Read More »

Forward Looking Statements

Any statements contained in this blog that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K.

This Blog is official and sanctioned by DelMar Pharmaceuticals, Inc.

Get DelMar Pharmaceuticals, Inc. Blog Post Alerts